drugset / Trial / NCT04313647

A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

NCT04313647 ↗

Phase 1 Completed 24 enrolled Ruijin Hospital Shanghai AbelZeta Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Exosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers with the abundance of adhesive proteins that readily interact with cellular membranes. These vesicles have a content that includes cytokines and growth factors, signaling lipids, mRNAs, and regulatory miRNAs. Exosomes are involved in cell-to-cell communication, cell signaling, and altering cell or tissue metabolism at short or long distances in the body, and can influence tissue responses to injury, infection, and disease. Experimental studies have demonstrated that mesenchymal stem cells (MSCs) or their exosomes (MSCs-Exo) significantly reduced lung inflammation and pathological impairment resulting from different types of lung injury. In addition, macrophage phagocytosis, bacterial killing and outcome were improved. It is highly likely that MSCs-Exo have the similar therapeutic effect on inoculation pneumonia as MSCs themselves. This clinical study will be performed to evaluate the safety and tolerance of aerosol inhalation of the exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exo) in healthy volunteers.

Timeline

Start
2020-03-12
Primary completion
2020-04-30
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MSCs-Exo Other / unclassified 2e+08 unknown Inhaled
Subject MSCs-Exo Other / unclassified 4e+08 unknown Inhaled
Subject MSCs-Exo Other / unclassified 8e+08 unknown Inhaled
Subject MSCs-Exo Other / unclassified 1.2e+09 unknown Inhaled
Subject MSCs-Exo Other / unclassified 1.6e+09 unknown Inhaled

Indications

No indication recorded.